Recent advances in the management of leukaemia

Current Paediatrics

Volumn 13, Issue 3, 2003, Pages 201-206

  Will, Andrew ^a  

^a ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Advances; Chronic myeloid leukaemia; Leukaemia; Paediatric

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYTARABINE; CYTOSINE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; IMATINIB; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; BLAST CELL; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CAUSE OF DEATH; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; CYTOGENETICS; DRUG ACTIVITY; DRUG MECHANISM; HUMAN; INFECTION; LIVER TOXICITY; MORTALITY; PATHOPHYSIOLOGY; PROGNOSIS; RISK; SIDE EFFECT; VEIN OCCLUSION;

EID: 0037541057     PISSN: 09575839     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0957-5839(03)00024-1     Document Type: Conference Paper

References (20)

1. Stevens R F, Hann I M, Wheatley K, Gray R G. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council's 10th AML trial. Br J Haematol 1998; 101: 130-140.
2. Eden O B, Harrison G, Richards S et al. Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-1997. Leukaemia 2000; 12: 2307-2320.
3. The United Kingdom Childhood Cancer Case Control Study of exposure to domestic sources of ionizing radiation. I. Radon gas. Br J Cancer 2002; 86: 1721-1726.
4. The United Kingdom Childhood Cancer Case Control Study of exposure to domestic sources of ionizing radiation. II. Gamma irradiation. Br J Cancer 2002; 86: 1727-1731.
5. Weimels J L, Cazzaniga G, Daniotti M et al. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet 1999; 354: 1499-1503.
6. Weimels J L, Xiao Z, Buffler P A et al. In utero origin of t(8;21) AMLI-ETO translocations in childhood acute myeloid leukaemia. Blood 2002; 99: 3801-3805.
7. Awan A, Taylor G M, Gokhale D A et al. Increased frequency of Fanconi anaemia group C genetic variants in children with sporadic acute myeloid leukaemia. Blood 1998; 91: 4813-4814.
8. Hargrave D R, Hann I M, Richards S M et al. Progressive reduction in treatment-related deaths in Medical Research Council childhood lymphoblastic leukaemia trials from 1980-1997 (UKALL VIII, X and XI). Br J Haematol 2001; 112: 293-299.
9. Harrison C J, Martineau M, Secker-Walker L M. The Leukaemia Research Fund/United Kingdom Cancer Cytogenetics Group Karyotype Database in acute lymphoblastic leukaemia: a valuable resource for patient management. Br J Haematol 2001; 113: 3-10.
10. Harrison C J. The management of patients with leukaemia: the role of cytogenetics in this molecular era. Br J Haematol 2000; 108: 19-30.
11. Goulden N, Oakhill A, Steward C. Practical application of minimal residual disease assessment in childhood acute lymphoblastic leukaemia. Br J Haematol 2001; 112: 275-281.
12. Eden O B. Translation of cure for acute lymphoblastic leukaemia to all children. Br J Haematol 2002; 118: 945-951.
13. Chessells J M. The management of high-risk leukaemia in children. Br J Haematol 2000; 108: 204-216.
14. Wheatley K, Burnett A K, Goldstone A H et al. A simple, robust, validated and highly predictive index for the determination of riskdirected therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 1999; 107: 69-79.
15. Parker J, Pagliuca A, Mijovic A et al. Fludarabine, cytarabine, G-CSF and idarubicin (Flag-Ida) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia. Br J Haematol 1997; 99: 959-944.
16. Estey E, Thall P, Andreeff M et al. Use of G-CSF before, during and after fludarabine and ara-C induction chemotherapy of newly diagnosed AML or MDS: comparison with fludarabine + Ara-C without G-CSF. J Clin Oncol 1994; 671-678.
17. Mayer R J, Davis R B, Schiffer C A et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994; 331: 896-903.
18. Sievers E L, Larson Rarjian A, Stadtmauer E A et al. Efficacy and safety of Gemtuzumab in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19: 3244-3254.
19. Giles F J, Kantarjian H M, Kornblau S M et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 2001; 15: 406-413.
20. Kantarjian H, Sawyers C, Hochhaus A et al. Hematologic and cytogenetic responses to Imatinib mesylate in chronic myeloid leukaemia. N Engl J Med 2002; 346: 645-652.